AN UNCOMMON CAUSE OF HEART FAILURE: ACROMEGALIC CARDIOMYOPATHY CULMINATING IN ORTHOTOPIC HEART TRANSPLANTATION
Aditya Dewanjee(Alaska Heart and Vascular Institute), Raghav Gattani(Brigham and Women's Hospital), Palak Shah(Alaska Heart and Vascular Institute), Shashank Desai(Dr. Reddy's Laboratories (India)), Shashank S. Sinha(Inova Fairfax Hospital), Christopher King(National Institute of Neurological Disorders and Stroke), Anika Raja(Alaska Heart and Vascular Institute), Mitchell A. Psotka(Alaska Heart and Vascular Institute), Behnam Nonahal Tehrani(Alaska Heart and Vascular Institute), Hala Moukhachen(Alaska Heart and Vascular Institute), Moemen Eltelbany(Inova Health System), Jamie L.W. Kennedy(Inova Fairfax Hospital), Danny Rayes(Georgetown University), Daniel Giunway Tang(Alaska Heart and Vascular Institute), Edward William Howard(Alaska Heart and Vascular Institute), Ramesh Singh(Alaska Heart and Vascular Institute), Karl D. Young(Alaska Heart and Vascular Institute)
Cited by 2
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update
|The Journal of Heart and Lung Transplantation|2023|307
Criteria for Defining Stages of Cardiogenic Shock Severity
|Journal of the American College of Cardiology|2022|283
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
|European Heart Journal|2022|213